[ad_1]
Johnson & Johnson surpassed analysts' estimates of quarterly profits and profits Tuesday, due to higher drug sales for unusual diseases.
The health conglomerate achieved these results after the acquisition of the firm Actelion and anti-cancer drugs Zytiga and Darzalex.
Sales in the three largest units of the company increased, and revenues of pharmaceutical companies rose by almost 20% to 10 thousand 350 million dollars nearly half of total sales of the second quarter.
The company's shares were volatile in transactions prior to Wall Street and were recovering from a decline to trade 1.4% to $ 126.46.
On the other hand, J & J agreed to appeal a court decision in Missouri, which ordered the company to pay a record $ 4,690 million to 22 women who reported that their cancer had been caused by the talc made by the company.
In addition, Johnson & Johnson faces about 9 thousand lawsuits that point to his talc-based products, including his baby powder, causing ovarian cancer and the mesothelioma, a rare cancer linked to asbestos
The company has denied that these products contain asbestos or cause cancer of any kind.
The net profits of the company increased to 3 thousand 950 million dollars, or 1.45 dollars per share, in the second quarter, against 3 thousand 830 million, or 1.40 dollars per share, for the same period in 2017. [19659009Excludingthepecialcomponentsthecompanyadvanceddelivered$210persharebeyondtheaverageestimateof$207perpaperweight
Source link
